Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 4/20 | 0.44 |
| ▸ | METAP1 | P53582 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5288710 | 0.88 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1METAP2METAP1 | |
| SCHEMBL5638282 | 0.82 | CYP2C9 (0.46) | METAP2METAP1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL5321615 | 0.81 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1ALDH1A1CYP2C9 | |
| SCHEMBL7366366 | 0.77 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1METAP2METAP1 | |
| SCHEMBL5326799 | 0.77 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1METAP2METAP1 | |
| SCHEMBL19682744 | 0.77 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1METAP2METAP1 | |
| SCHEMBL26966061 | 0.77 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1METAP2METAP1 | |
| SCHEMBL29628527 | 0.77 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1METAP2METAP1 | |
| SCHEMBL21870762 | 0.77 | GPR84 (0.61) | SLC6A4 | |
| SCHEMBL20551986 | 0.77 | GPR84 (0.61) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC1A3 4472/4885SLC1A2 4787/4885SLC1A1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.